Antidepressants, sleeping pills and anxiety drugs may increase driving risk

12 September 2012

Drugs prescribed to treat anxiety, depression and insomnia may increase patients’ risk of being involved in motor vehicle accidents, according to a recent study published in the British Journal of Clinical Pharmacology. Based on the findings, the researchers suggested doctors should consider advising patients not to drive while taking these drugs.

Psychotropic drugs affect the way the brain functions and can impair a driver’s ability to control their vehicle. Research on the links between psychotropic medication and driving accidents has focused on benzodiazepines, which have been used to treat anxiety and insomnia. Perhaps the best known of these drugs is diazepam. Newer “Z-drugs,” used to treat insomnia, have received less attention, as have antidepressants and antipsychotics.

To understand the effects of a wider spectrum of psychotropic drugs on driving accidents, the authors compared drug use in two groups of people identified using medical records from the Taiwanese national health insurance program. The first group included 5,183 people involved in motor vehicle accidents. The second group included 31,093 people, matched for age, gender and the year of vehicle accidents, who had no record of being involved in motor vehicle accidents. In general, those involved in accidents were more likely to have been taking psychotropic drugs, whether they had been taking them for one month, one week or one day.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical